The power of creativity www.originbranding.com. Pharmaceutical Branding 2012



Similar documents
Outcomes of Monitoring Committee Reviews. Medicines Australia Code of Conduct

CHEM-E4140 Selectivity 12. Pharma Business

Decision Matrix: Selecting a CRM Vendor in the Pharmaceutical Market (Competitor Focus)

Stakeholder Insight: Insulin Use in Type 2 Diabetes

Pharma working capital performance highly variable

Stakeholder Perspectives: Mild Cognitive Impairment and Dementia

KEEPING CLINICAL TRIALS IN AUSTRALIA

Commercial Insight Osteoarthritis and Rheumatoid Arthritis

Annual Press Conference Business Year 2011

Join our scientific talent community

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors

December 17, 2014 HOW PHARMA MARKETERS FIND AND SELECT DIGITAL MARKETING AGENCIES

Key Findings. Use this report to... The Autoimmune Market Outlook to 2013

ehealthinsight Series: Online Patient Recruitment Strategies

Chapter 1 INTRODUCTION GLOBAL MARKETS FOR EMERGING INSULIN DRUG AND DELIVERY TECHNOLOGIES HLC149A. Shalini Shahani Dewan Project Analyst

Commercial Perspectives: Multiple Sclerosis

New Treatments. For Bipolar Disorder. Po W. Wang, MD Clinical Associate Professor Bipolar Disorders Clinic Stanford University School of Medicine

e-labeling : innovation for patient or regulation nightmare Pharmapack Feb, 11 th, 2015

Pharmaceutical Marketing Disclosures

Pharma RepTrak 2015 The World s Most Reputable Pharmaceutical Companies

The Evolution of Data Platforms in IMI. Anthony Rowe, Janssen R&D IT 08 April 2016 Med-e-Tel Luxembourg

Bayer Pharma AG Berlin Germany Tel News Release. Not intended for U.S. and UK Media

Abnormal Uterine Bleeding FAQ Sheet

US Diabetic Devices Industry Research Report: KenResearch

Liver Function Essay

EBiSC the first European bank for induced pluripotent stem cells

GLOBAL MARKETS FOR EMERGING INSULIN DRUG AND DELIVERY TECHNOLOGIES - FOCUS ON INSULIN PENS. HLC157A August Shalini Shahani Dewan Project Analyst

THE BIOTECH & PHARMACEUTICAL INDUSTRY

Pharma working capital leaves room for improvement

Oracle Buys Phase Forward Expands Oracle s solutions for the life sciences and healthcare industries

Prior Authorization Guideline

Medicare Drug Coverage Under Part A, Part B, and Part D

group insurance The Tiered Plan with Dynamic Therapeutic Formulary Why pay more than you have to for your prescription drugs?

SHORT CLINICAL GUIDELINE SCOPE

Multiple Sclerosis. Current and Future Players. GDHC1009FPR/ Published March 2013

EINSTEIN PE Data Summary & Perspectives on XARELTO (rivaroxaban) in ORS & NVAF. Recorded Webcast Update for Analysts and Investors March 26, 2012

Small-Cell Lung Cancer Global Clinical Trials Review, H2, 2015

Go for the complete package.

Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer

novo nordisk Partnering for innovation IN PROTEIN-BASED THERAPEUTICS AND TECHNOLOGIES Protein Technologies Diabetes Protein Delivery Devices

A list of all medications you are taking also include any vitamins, supplements, over-the-counter medicines, or herbal products

Avoca s Quality Metrics Consulting Service Offering

Erectile Dysfunction (ED)

Q Conference Call

TO: HELENA SALES, POC SPECALISTS, INTERNATIONAL DISTRIBUTORS FROM: HELENA HEMOSTASIS/POINT OF CARE SUBJECT: ROUND-UP DATE: 11/10/2010

The Swedish Drug Development Pipeline June A survey conducted by:

Global Non-Small Cell Lung Cancer Therapeutics Market

6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality

A PATIENT S GUIDE TO DEEP VEIN THROMBOSIS TREATMENT

TABLE OF COMMITMENTS

LOW T NATION TESTOSTERONE INTAKE FORM NAME: DATE: ADDRESS: CITY: STATE: ZIP: CELL #: HOME #: SOC SECURITY #: DATE OF BIRTH:

Analyzing the Global Diabetes Market 2016

Certificate of Equivalence of Core Surgical Training

Introduction to Insulin. Your guide to taking insulin

sexual after Being prostate cancer... Manitoba Prostate Centre Visit our website at

Global Peptide Therapeutics Market

PROGRAM PLAN FOR THE ONTARIO MEDICATIONS RETURN PROGRAM

CODE FOR DISCLOSURE OF TRANSFERS OF VALUE BY PHARMACEUTICAL COMPANIES TO HEALTHCARE PROFESSIONALS AND HEALTH ORGANIZATIONS

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November :38

PULMONARY ARTERIAL HYPERTENSION AGENTS

Scott Byrne & Rachel Weeks G400: Pharma Report 10/22/09 Direct to Consumer Advertising: The Affect on the Pharmaceutical Industry

February page 1 / 9

Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness SOGH April

Outsourcing and Offshoring of R&D in the Pharmaceutical Industry: Evidence and Policy Implications from a Global Value Chain Analysis

Are insulin analogs worth their cost in type 2 diabetes?

Integrated Approach to Build Patient Adherence: Helping Pharmaceutical Companies to Enhance Growth

Shared Care Agreement Insulin Degludec (Tresiba )

Company Presentation June 2011 Biotest AG 0

Portfolio of Offerings

Pipeline Insight: Schizophrenia Asenapine; A future market leader?

East Kent Prescribing Group

Summary of the risk management plan (RMP) for Xultophy (insulin degludec / liraglutide)

Investor News. Not intended for U.S. and UK media

Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, Single User License: US $ 4595

BOLT Hem/Onc Thought Leader Panel #38 Cancer Immunotherapy

The Cell Therapy Catapult

In the largest and perhaps the most ambitious collaborative

Pharmaceutical industry

Traveller s Thrombosis. Dr. Peter Verhamme Vascular Medicine and Haemostasis UZ Leuven

from PKI to Identity Assurance

Catheter Embolization and YOU

How To Get A Dose Of Bayer Healthcare'S Oral Anticoagulant, Xarelto

Clinical trial research agreement Agreed schedule 4 or 7 clause amendments

Transcription:

The power of creativity www.originbranding.com Pharmaceutical Branding 2012

We are an independent, boutique agency passionately focused on developing pharmaceutical brands. For over 15 years we have delivered outstanding branding solutions for our clients from our offices in Surrey, UK and Birmingham, Michigan. Developing a brand identity that communicates your brand message, ensures differentiation and clears the relevant trademark screening and regulatory checks can be a challenging task. Our proven branding process has been built on creativity, flexibility and a strong understanding of all the issues and challenges surrounding the registration of a new identity, irrespective of geographical or business area. Many examples of our naming, design and research projects are presented in the following pages and additional examples of our work in the pharmaceutical and other industries can be found in our website. We look forward to speaking with you about your branding challenges! Abbott Products Allergan Alliance Pharma Astellas AstraZeneca Axis-Shield Baxter Bayer BD Biotest DuoCort DuPont Ferring Fresenius Galderma Grünenthal GlaxoSmithKline Intercytex Intervet Janssen Pharmaceutica Johnson & Johnson Lundbeck Merck Merck Serono Novartis Novo Nordisk Nycomed Orion Pharma Procter & Gamble Pfizer Philips Medical Roche Shire Sanofi UCB

Janssen Pharmaceutica - Xeplion Janssen Pharmaceutica s once monthly, long-acting injectable, antipsychotic for the treatment of schizophrenia. Xeplion is a dynamic, impactful, strong and modern sounding name reflecting the innovative approach to the treatment. DuoCort - Plenadren DuoCort s new treatment for Addison s disease, a rare and life threatening adrenal insufficiency disease. Instantly meaningful and easily communicated, Plenadren is derived from plenty and adrenal and conveys confidence, re-assurance and increased control. Abbott Products Allergan Alliance Pharma Astellas AstraZeneca Axis-Shield Baxter Bayer BD Biotest DuoCort DuPont Ferring Fresenius Galderma Grünenthal GlaxoSmithKline Intercytex Intervet Janssen Pharmaceutica Johnson & Johnson Lundbeck Merck Merck Serono Novartis Novo Nordisk Nycomed Orion Pharma Procter & Gamble Pfizer Philips Medical Roche Shire Sanofi UCB

Bayer - Levitra ODT Origin created the Levitra brand name for Bayer and were later asked to create an innovative, added-value packaging for the new ODT formulation. We created a unique system that included a pull out tab containing key information for the patient. The blister pack is encased in a discreet matt black sleeve to create a luxurious and empowering user experience. Bayer and Johnson & Johnson - Xarelto Bayer and Johnson & Johnson s oral anti-coagulant to prevent blood clots after orthopaedic surgery. Xarelto is a ground breaking new factor Xa inhibitor. The name is modern, impactful and resonates with prescribers and patients alike, characteristics that re-enforce the key brand message. Abbott Products Allergan Alliance Pharma Astellas AstraZeneca Axis-Shield Baxter Bayer BD Biotest DuoCort DuPont Ferring Fresenius Galderma Grünenthal GlaxoSmithKline Intercytex Intervet Janssen Pharmaceutica Johnson & Johnson Lundbeck Merck Merck Serono Novartis Novo Nordisk Nycomed Orion Pharma Procter & Gamble Pfizer Philips Medical Roche Shire Sanofi UCB

Firmagon Packaging development for a hormonal therapy for prostate cancer Omnic Wowtab Visual identity for an orodispersible urology formulation for Astellas Replagal An enzyme replacement therapy for patients with Fabry disease Elaprase Indicated for patients with Hunter syndrome Posidorm A new brand of melatonin that promotes better sleep in a variety of sleep disorders Flomaxtra Brand Identity for a BPH (Benign Prostatic Hyperplasia) treatment

Shire - Elaprase Elaprase is indicated for patients with Hunter syndrome. A global set of packaging including over 500 pieces of artwork was created for use across all countries applying the latest regulatory information. Abbott Products Allergan Alliance Pharma Astellas AstraZeneca Abbott (Solvay) - Creon Axis-Shield Baxter Origin consolidated a variety of differing brand logos to Bayer create a single global presence. This new identity capitalises BD Biotest on Solvay s expertise and Creon s patented minimicrosphere DuoCort technology which allows appropriate delivery of enzymes DuPont into the body. Ferring Fresenius Galderma Grünenthal GlaxoSmithKline Intercytex Intervet Janssen Pharmaceutica Johnson & Johnson Lundbeck Merck Merck Serono Novartis Novo Nordisk Nycomed Orion Pharma Procter & Gamble Pfizer Philips Medical Roche Shire Sanofi UCB

NovoPen Echo Insulin pen from Novo Nordisk designed for children with diabetes ACCU-CHEK Inform Roche Diagnostics fully integrated portable blood glucose testing system Isprelor A name and logo of misoprostol for Alliance Pharmaceuticals Nexiva BD Nexiva Closed IV Catheter System Omnifuse Infusion syringe pump system for Smiths Industries Afinion A point of care multiparameter analyser system for Axis-Shield

Afinitor Novartis treatment for renal cell carcinoma Caprelsa AstraZeneca s kinase inhibitor indicated for thyroid cancer Selincro Lundbeck s treatment for alcohol dependency Levitra Erectile dysfunction drug, co-marketed by Bayer and GSK Prezista HIV protease inhibitor from Tibotec Zutectra Biotest s drug for the prevention of hepatitis B after liver transplantation

Brand naming Brand name generation Tagline/brand statement development Brand naming architecture INN name generation Brand design Symbol/logotype development Packaging design Identity guidelines Pharmaceutical artwork Brand strategy Strategic brand analysis Portfolio analysis Brand extension/ positioning Visual brand evaluation Brand market research Brand equity/awareness studies Name validation Linguistic screening Trademark/legal pre-screening Safety testing Scriptability testing UK Office: Bridge House, 72 Bridge Road, East Molesey, Surrey KT8 9HF Tel: +44(0)20 8941 5811 US Office: 200 Elm Street, Birmingham, MI 48009 Tel: +1 248 723 7833